nCounter® CAR-T Characterization Panel
Helping Your Research
The nCounter CAR-T Characterization Panel was created in collaboration with experts in CAR-T therapy to facilitate the development of robust product release assays. Confidently profile CAR-T products for research and manufacturing applications with an automated, and reproducible assay. Ideally suited for new CAR-T development and QC, the CAR-T Characterization Gene Expression Panel can help streamline the CAR-T manufacturing workflow and potentially reduce vein to vein time. This panel can measure eight essential components of CAR-T biology with 780 human genes.
Empower your knowledge of CAR-T with the most up-to-date biology developed with experts in the field.
- Optimize CAR-T method development
- Create manufacturing acceptance criteria
- Measure metabolic fitness and persistence
- Monitor post-infusion exhaustion and toxicity
How It Works
CAR-T Therapy Workflow
Understanding each step of the CAR-T workflow is critical to ensuring quality and efficacy of the final CAR-T product. The nCounter CAR-T Characterization Panel can be used throughout development and manufacturing as a standardized panel of genes for optimizing methods, developing manufacturing acceptance criteria as well as understanding the host influences beyond manufacturing.
In addition to the standard nSolver™ Analysis, genes included in the CAR-T Characterization panel are organized and linked to various advanced analysis modules to allow for efficient exploration of the eight essential aspects of CAR-T biology.
Advanced Analysis Modules Available for CAR-T Characterization
- Quality Control
- Pathway Analysis
- Cell Profiling
- Differential Expression
- Gene Set Analysis
- Built-in Compatibility for Panel Plus and Protein Analysis
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
NanoString is excited to be working with Servier (as project leader), Bayer, Janssen, and Takeda as partners with the Innovative Medicines Initiative (IMI) Consortium in the European Union to develop gold standard analytical methods to use throughout development, manufacturing, and delivery of CAR-T cell therapies. The IMI is the largest public-private partnership in the world dedicated to health research.
Immune Monitoring for Advanced Cell Therapy Trials in Transplantation: Which Assays and When?
A number of immune regulatory cellular therapies, including regulatory T cells and mesenchymal stromal cells, have emerged as novel alternative therapies for the control of transplant alloresponses. Clinical studies have demonstrated their feasibility and safety, however developing our understanding of the impact of cellular therapeutics in vivo requires advanced immune monitoring strategies.
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.
High expression levels of human epidermal growth factor receptor 2 (HER2) have been associated with poor prognosis in patients with pancreatic adenocarcinoma (PDAC). However, HER2-targeting immunotherapies have been unsuccessful to date.
Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing.
The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient’s leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of cell populations that might negatively affect production of chimeric antigen receptor (CAR) T cells, such as myeloid cells.